MediciNova CMO granted option for 350,000 shares

MediciNova Inc.'s Chief Medical Officer, Matsuda Kazuko, reported a performance-based equity award on Form 4.

Rhea-AI Filing Summary

MediciNova Inc.'s Chief Medical Officer, Matsuda Kazuko, reported a performance-based equity award on Form 4. On January 16, 2026, the officer acquired an employee stock option to buy 350,000 shares of common stock at an exercise price of $2.10 per share, expiring on January 6, 2035. According to the disclosure, this option was originally granted on January 7, 2025 and was tied to performance criteria for the fiscal year ended December 31, 2025. Those criteria were met, resulting in full vesting of the 350,000-share option, which is now directly owned and fully exercisable.

Insider Trade Summary

Grant/Award: 350,000 shares

Grant/Award 1 txn

Insider Matsuda Kazuko

Role Chief Medical Officer

Type	Security	Shares	Price	Value
Grant/Award	Employee Stock Option (Right to Buy)	350,000	$0.00	$0.00

Holdings After Transaction: Employee Stock Option (Right to Buy) — 350,000 contracts (Direct)

Footnotes (1)

1. F1. On January 7, 2025, the reporting person was granted an option to purchase 350,000 shares of common stock. The option vests based on the satisfaction of certain performance criteria for the fiscal year ended December 31, 2025. Such performance criteria for 2025 were met, resulting in full vesting of the option.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

Who is the reporting insider in MediciNova (MNOV)'s latest Form 4?

The reporting person is Matsuda Kazuko, who serves as Chief Medical Officer of MediciNova Inc. and is classified as an officer but not a director or 10% owner.

What transaction did MediciNova's Chief Medical Officer report on January 16, 2026?

The Chief Medical Officer reported the acquisition of an employee stock option (derivative security) covering 350,000 shares of common stock, coded as transaction type A (grant or award) on January 16, 2026.

What are the key terms of the 350,000-share stock option reported by MediciNova's CMO?

The option allows the purchase of 350,000 shares of common stock at an exercise price of $2.10 per share. It became exercisable on January 16, 2026 and carries an expiration date of January 6, 2035.

How did performance criteria affect the MediciNova CMO's 350,000-share option?

The filing states that the option was originally granted on January 7, 2025 and would vest based on meeting performance criteria for the fiscal year ended December 31, 2025. Those criteria were met, resulting in full vesting of the 350,000-share option.

How many derivative securities does the MediciNova CMO hold after this Form 4 transaction?

Following the reported transaction, the Chief Medical Officer beneficially owns 350,000 employee stock options directly, each representing the right to buy one share of MediciNova common stock.

Is the MediciNova CMO's stock option held directly or indirectly?

The Form 4 lists the ownership form of the option as Direct (D), with no nature of indirect beneficial ownership disclosed.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 01/20/2026 - 05:04 PM EST Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Matsuda Kazuko

(Last) (First) (Middle)

C/O MEDICINOVA, INC.

4275 EXECUTIVE SQUARE, SUITE 300

(Street)

LA JOLLA CA 92037

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
MEDICINOVA INC [ MNOV ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Medical Officer

3. Date of Earliest Transaction (Month/Day/Year)
01/16/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Employee Stock Option (Right to Buy)	$2.1	01/16/2026		A		350,000		01/16/2026	01/06/2035	Common Stock	350,000	$0	350,000(1)	D

Explanation of Responses:

1. On January 7, 2025, the reporting person was granted an option to purchase 350,000 shares of common stock. The option vests based on the satisfaction of certain performance criteria for the fiscal year ended December 31, 2025. Such performance criteria for 2025 were met, resulting in full vesting of the option.

	/s/ Yuichi Iwaki, attorney-in-fact	01/20/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.